Femasys Inc. (FEMY) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Femasys Inc., a Delaware corporation, on January 19, 2022. The report details corporate governance changes effective as of January 19, 2022, specifically regarding the composition of the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters and does not contain financial performance data.
Material Changes
- Director Resignation: William Witte resigned from the Board of Directors effective January 19, 2022. The resignation was not the result of any disagreement with the Company.
- Director Election: Wendy Perrow was elected as a new director to fill the vacancy. She is designated as a Class II director with a term expiring at the annual meeting following the year ending December 31, 2022.
- Committee Appointments: Ms. Perrow will serve on the Compensation Committee. Anne Morrisey, a current director, was appointed to the Nominating and Governance Committee.
Outlook, Commentary, and Risks
The Board of Directors stated that Ms. Perrow was selected due to her extensive experience as a biotechnology entrepreneur and leader in innovative biotech and pharmaceutical ventures. Her background includes roles as CEO of AsclepiX Therapeutics and Alba Therapeutics, as well as leadership positions at Sigma-Tau Pharmaceuticals, Merck & Co., and Johnson & Johnson. The Board highlighted her expertise in expediting growth, profitability, and fundraising.
Ms. Perrow will receive an annual retainer and equity awards consistent with the Company's director compensation policy and will enter into an indemnification agreement. No specific risks or contingencies were disclosed in this filing.
Key Facts for Investor Verification
- Confirm the effective date of William Witte's resignation and Wendy Perrow's election (January 19, 2022).
- Verify Ms. Perrow's specific committee assignments (Compensation Committee) and term expiration (following the 2022 annual meeting).
- Review the Company's director compensation policy to understand the specific equity awards and retainer amounts applicable to Ms. Perrow.
- Check for any subsequent filings regarding the status of the Nominating and Governance Committee following Anne Morrisey's appointment.